Host: John J. Russell, MD

Guest: Ralph A. DeFronzo, MD

Leading Endocrinologist, Dr. Ralph A. DeFronzo joins host Dr. John Russell to discuss, "A Look at a GLP-1 Treatment Option for Adult Patients with Type 2 Diabetes" brought to you by AstraZeneca. Dr. DeFronzo will review BYETTA® (exenatide) injection, prescribing and usage guidelines; results of the 4B Study; and, potential risks and benefits of BYETTA. Dr. DeFronzo is Professor of Medicine, the Chief of the Diabetes Division at the University of Texas Health Science Center, and the Deputy Director of the Texas Diabetes Institute, San Antonio, Texas.

Brought to you by

Important Safety Information (ISI)

Contraindications

• BYETTA® (exenatide) injection is contraindicated in patients with prior severe hypersensitivity reactions to exenatide or to any of the product components.

Warnings and Precautions

• Never Share a BYETTA Pen Between Patients: Pen-sharing poses a risk for transmission of blood-borne pathogens, even if the needle is changed.
• Pancreatitis: Based on postmarketing data BYETTA has been associated with acute pancreatitis, including fatal and non-fatal hemorrhagic or necrotizing pancreatitis. After initiation and dose increases of BYETTA, observe patients carefully for pancreatitis ...